NcXHF

Recommendations

Info

Contents 2015 ASCO Annual Meeting Disclosure xiv 2014–2015 Cancer Education Committee xv 2015 Educational Book Expert Panel xvi 2015 Annual Meeting Supporters xx Letter from the Editor 1 INVITED ARTICLES The Changing Landscape of Phase I Trials in Oncology Kit Man Wong, Anna Capasso, and S. Gail Eckhardt 3 Genomics, Personalized Medicine, and Supportive Cancer Care Stephen T. Sonis 9 Clinical Research in Metastatic Prostate Cancer: A Focus on Impact and Value Maha Hussain and Robert S. DiPaola 17 The Future of Molecular Medicine: Biomarkers, BATTLEs, and Big Data Edward S. Kim 22 Towards a Personalized Treatment of Head and Neck Cancer Andrew M. Gross and Ezra E.W. Cohen 28 Medical Education: Perils and Progress in Educating and Assessing a New Generation of Learners Jill Gilbert, Helen Chew, Charlene Dewey, and Leora Horn 33 Perspectives on Clinical Trials for Gastrointestinal Malignancies Cathy Eng, Nancy Roach, Michele Longabaugh, and George Fisher 40 I Will Recommend a Clinical Trial—If I Can William M. Sikov 44 BREAST CANCER Challenging Issues in Metastatic Disease Precision Medicine for Metastatic Breast Cancer Elise Deluche, Elisa Onesti, and Fabrice Andre Surgery or Ablative Radiotherapy for Breast Cancer Oligometastases Joseph K. Salama and Steven J. Chmura eArticle eArticle The 2015 ASCO Educational Book is published online at asco.org/edbook. Articles can also be accessed from the Attendee Resource Center at am.asco.org/ARC. Articles that are included in this print edition include a page number reference in the table of contents. asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK iii
Page 1 and 2: AMERICAN SOCIETY OF CLINICAL ONCOLO
Page 3: American Society of Clinical Oncolo
Page 7 and 8: ICD-10: History, Implementation, an
Page 9 and 10: GENITOURINARY CANCER Beyond Tyrosin
Page 11 and 12: CD19 CAR Therapy for Acute Lymphobl
Page 13 and 14: Locoregional Therapies in the Setti
Page 15 and 16: TUMOR BIOLOGY Implications of Intra
Page 17 and 18: 2014-2015 Cancer Education Committe
Page 19 and 20: Monica Fornier, MD Memorial Sloan K
Page 21 and 22: Anna Varghese, MD Memorial Sloan Ke
Page 23 and 24: HELSINN Health Services Research an
Page 25 and 26: Letter from the Editor On behalf of
Page 27 and 28: INVITED ARTICLES METHODS The Changi
Page 29 and 30: THE CHANGING LANDSCAPE OF PHASE I T
Page 31 and 32: THE CHANGING LANDSCAPE OF PHASE I T
Page 33 and 34: INVITED ARTICLES PALLIATIVE CARE Ge
Page 35 and 36: GENOMICS, PERSONALIZED MEDICINE, AN
Page 41 and 42: INVITED ARTICLES GENITOURINARY CANC
Page 43 and 44: CLINICAL TRIALS FOR METASTATIC PROS
Page 45 and 46: CLINICAL TRIALS FOR METASTATIC PROS
Page 47 and 48: THE FUTURE OF MOLECULAR MEDICINE pa
Page 49 and 50: THE FUTURE OF MOLECULAR MEDICINE ph
Page 51 and 52: THE FUTURE OF MOLECULAR MEDICINE 10
Page 53 and 54: PERSONALIZED TREATMENT OF HEAD AND
Page 55 and 56:
PERSONALIZED TREATMENT OF HEAD AND
Page 57 and 58:
INVITED ARTICLES PROFESSIONAL DEVEL
Page 59 and 60:
MODERN DAY MEDICAL EDUCATION TABLE
Page 61 and 62:
MODERN DAY MEDICAL EDUCATION E-Lear
Page 63 and 64:
MODERN DAY MEDICAL EDUCATION New MD
Page 65 and 66:
CLINICAL TRIALS AND GI MALIGNANCIES
Page 67 and 68:
CLINICAL TRIALS AND GI MALIGNANCIES
Page 69 and 70:
I WILL RECOMMEND A CLINICAL TRIAL
Page 71 and 72:
BREAST CANCER Challenging Issues in
Page 73 and 74:
PRECISION MEDICINE FOR METASTATIC B
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
ABLATIVE THERAPY FOR OLIGOMETASTATI
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
CONTROVERSIES IN BREAST CANCER NEOA
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
PUNGLIA, HUGHES, AND MUSS Managemen
Page 97 and 98:
PUNGLIA, HUGHES, AND MUSS TABLE 1.
Page 99 and 100:
PUNGLIA, HUGHES, AND MUSS TABLE 2.
Page 101 and 102:
PUNGLIA, HUGHES, AND MUSS 6. Hughes
Page 103 and 104:
BREAST CANCER New Targets and Thera
Page 105 and 106:
DISIS AND STANTON cells to become t
Page 107 and 108:
DISIS AND STANTON TABLE 1. Unique C
Page 109 and 110:
DISIS AND STANTON 24. Gatalica Z, S
Page 111 and 112:
LEHMANN, PIETENPOL, AND TAN Neoadju
Page 113 and 114:
LEHMANN, PIETENPOL, AND TAN 3.8% to
Page 115 and 116:
LEHMANN, PIETENPOL, AND TAN stage I
Page 117 and 118:
LEHMANN, PIETENPOL, AND TAN cancer:
Page 119 and 120:
BREAST CANCER Optimizing Treatment
Page 121 and 122:
STEPHEN K. CHIA TABLE 1. Initial Re
Page 123 and 124:
STEPHEN K. CHIA with either weekly
Page 125 and 126:
STEPHEN K. CHIA trend was seen, the
Page 127 and 128:
STEPHEN K. CHIA B-41: an open label
Page 129 and 130:
KATHERINE D. CREW Addressing Barrie
Page 131 and 132:
KATHERINE D. CREW tion. 24 Despite
Page 133 and 134:
KATHERINE D. CREW assessment varied
Page 135 and 136:
KATHERINE D. CREW Breast cancer inc
Page 137 and 138:
KATHERINE D. CREW tosterone levels
Page 139 and 140:
CHRISTINE HOLMBERG alence of tamoxi
Page 141 and 142:
CHRISTINE HOLMBERG bers of women in
Page 143 and 144:
CHRISTINE HOLMBERG 40. Dillard AJ,
Page 145 and 146:
CANCER SCREENING AND SURVEILLANCE E
Page 147 and 148:
CANCER SCREENING AND SURVEILLANCE e
Page 149 and 150:
CANCER SCREENING AND SURVEILLANCE L
Page 151 and 152:
CANCER SCREENING AND SURVEILLANCE A
Page 153 and 154:
CANCER SCREENING AND SURVEILLANCE 6
Page 155 and 156:
HARVIE, HOWELL, AND EVANS Can Diet
Page 157 and 158:
HARVIE, HOWELL, AND EVANS TABLE 1.
Page 159 and 160:
HARVIE, HOWELL, AND EVANS TABLE 2.
Page 161 and 162:
HARVIE, HOWELL, AND EVANS Disclosur
Page 163 and 164:
CARE DELIVERY AND PRACTICE MANAGEME
Page 165 and 166:
POLITE, CONTI, AND WARD and Drug Ad
Page 167 and 168:
POLITE, CONTI, AND WARD 2024. Speci
Page 169 and 170:
POLITE, CONTI, AND WARD References
Page 171 and 172:
PAGE ET AL The Patient-Centered Med
Page 173 and 174:
PAGE ET AL $350 per month per patie
Page 175 and 176:
PAGE ET AL FIGURE 4. The COME HOME
Page 177 and 178:
PAGE ET AL FIGURE 6. Oncology PCMH
Page 179 and 180:
CARE DELIVERY AND PRACTICE MANAGEME
Page 181 and 182:
BOWMAN, CLELAND, AND STAGGS FIGURE
Page 183 and 184:
BOWMAN, CLELAND, AND STAGGS certif
Page 185 and 186:
BOWMAN, CLELAND, AND STAGGS Quality
Page 187 and 188:
BOWMAN, CLELAND, AND STAGGS sist wi
Page 189 and 190:
APPROACHES IN BRAIN METASTASES Targ
Page 191 and 192:
APPROACHES IN BRAIN METASTASES TABL
Page 193 and 194:
APPROACHES IN BRAIN METASTASES in p
Page 195 and 196:
APPROACHES IN BRAIN METASTASES 22.
Page 197 and 198:
RADIOTHERAPY AND RADIOSURGERY EVIDE
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
CENTRAL NERVOUS SYSTEM TUMORS Rare
Page 205 and 206:
MENINGIOMA MANAGEMENT TABLE 1. Meni
Page 207 and 208:
MENINGIOMA MANAGEMENT and 1p and 14
Page 209 and 210:
MENINGIOMA MANAGEMENT generally ran
Page 211 and 212:
MENINGIOMA MANAGEMENT 32. Hansson C
Page 213 and 214:
MENINGIOMA MANAGEMENT 109. Milosevi
Page 215 and 216:
ANTIBODY-DRUG CONJUGATES AND T-DM1
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
GERIATRIC ONCOLOGY AND CLINICAL TRI
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
GLOBALIZATION OF CLINICAL TRIALS cl
Page 233 and 234:
GLOBALIZATION OF CLINICAL TRIALS To
Page 235 and 236:
GLOBALIZATION OF CLINICAL TRIALS On
Page 237 and 238:
GLOBALIZATION OF CLINICAL TRIALS 29
Page 239 and 240:
NOVEL DESIGN STRATEGIES FOR TESTING
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
OVERCOMING RESISTANCE TO ANTI-EGFR
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
RESISTANCE TO ANTI-HER2 THERAPIES I
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
THE BATTLE AGAINST TKI RESISTANCE I
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
OPPORTUNITIES AND CHALLENGES FOR CL
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
PRECISION MEDICINE FOR BREAST CANCE
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
DEVELOPMENTAL THERAPEUTICS AND TRAN
Page 291 and 292:
MANAGING IMMUNE CHECKPOINT-BLOCKING
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
WEISER, ZHANG, AND SCHRAG Locally A
Page 301 and 302:
WEISER, ZHANG, AND SCHRAG Debilitat
Page 303 and 304:
WEISER, ZHANG, AND SCHRAG 16. Chau
Page 305 and 306:
BIOLOGIC THERAPIES IN COLORECTAL CA
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
SYSTEMIC TREATMENT FOR METASTATIC C
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
GASTROINTESTINAL (COLORECTAL) CANCE
Page 323 and 324:
TREATMENT OF COLORECTAL CANCER PERI
Page 325 and 326:
TREATMENT OF COLORECTAL CANCER PERI
Page 327 and 328:
HCC TUMOR BOARD: MAKING SENSE OF TH
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
GASTROINTESTINAL (NONCOLORECTAL) CA
Page 337 and 338:
PANCREATIC CANCER, IMMUNOTHERAPY, C
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
ASSESSMENT AND TREATMENT OF CACS Cu
Page 345 and 346:
ASSESSMENT AND TREATMENT OF CACS FI
Page 347 and 348:
ASSESSMENT AND TREATMENT OF CACS an
Page 349 and 350:
ASSESSMENT AND TREATMENT OF CACS f
Page 351 and 352:
ASSESSMENT AND TREATMENT OF CACS 61
Page 353 and 354:
KLIMSTRA ET AL The Spectrum of Neur
Page 355 and 356:
KLIMSTRA ET AL TABLE 1. Classificat
Page 357 and 358:
KLIMSTRA ET AL matin remodeling gen
Page 359 and 360:
KLIMSTRA ET AL disease and/or sympt
Page 361 and 362:
KLIMSTRA ET AL WD-NETs (grade 1 and
Page 363 and 364:
KLIMSTRA ET AL 63. Ito T, Sasano H,
Page 365 and 366:
GENITOURINARY CANCER Beyond Tyrosin
Page 367 and 368:
BEX, LARKIN, AND VOSS progression-f
Page 369 and 370:
BEX, LARKIN, AND VOSS limited expre
Page 371 and 372:
BEX, LARKIN, AND VOSS SIDEBAR. Fact
Page 373 and 374:
BEX, LARKIN, AND VOSS 23. Pal SK, H
Page 375 and 376:
GENITOURINARY CANCER Controversies
Page 377 and 378:
ALAN HORWICH second years, assessme
Page 379 and 380:
ALAN HORWICH clinical stage I nonse
Page 381 and 382:
GEORGE J. BOSL motherapy, and metab
Page 383 and 384:
GEORGE J. BOSL TABLE 1. Late Effect
Page 385 and 386:
GEORGE J. BOSL polycomb repressive
Page 387 and 388:
LAWRENCE H. EINHORN investigators c
Page 389 and 390:
GENITOURINARY CANCER Debate on Chem
Page 391 and 392:
HERNANDEZ-AYA AND HUSSAIN are recei
Page 393 and 394:
HERNANDEZ-AYA AND HUSSAIN amide, or
Page 395 and 396:
HERNANDEZ-AYA AND HUSSAIN nifıcant
Page 397 and 398:
DORFF AND GROSS Radium 223: How Can
Page 399 and 400:
DORFF AND GROSS 223 may confer fewe
Page 401 and 402:
GENITOURINARY CANCER Immunotherapy
Page 403 and 404:
SUSAN F. SLOVIN CHANGING THE TREATM
Page 405 and 406:
SUSAN F. SLOVIN ipilimumab. 17-19 P
Page 407 and 408:
SUSAN F. SLOVIN TABLE 2. Target Mol
Page 409 and 410:
SUSAN F. SLOVIN placebo-controlled
Page 411 and 412:
BRANCATO, LEWI, AND AGARWAL Evolvin
Page 413 and 414:
BRANCATO, LEWI, AND AGARWAL gamma i
Page 415 and 416:
BRANCATO, LEWI, AND AGARWAL frequen
Page 417 and 418:
BRANCATO, LEWI, AND AGARWAL 52. Sha
Page 419 and 420:
WEINSTOCK AND MCDERMOTT antigen-pre
Page 421 and 422:
WEINSTOCK AND MCDERMOTT metastatic
Page 423 and 424:
WEINSTOCK AND MCDERMOTT PD-1 in the
Page 425 and 426:
GENITOURINARY CANCER Integrating Ne
Page 427 and 428:
APOLO, VOGELZANG, AND THEODORESCU c
Page 429 and 430:
APOLO, VOGELZANG, AND THEODORESCU T
Page 431 and 432:
APOLO, VOGELZANG, AND THEODORESCU P
Page 433 and 434:
APOLO, VOGELZANG, AND THEODORESCU O
Page 435 and 436:
NONSURGICAL MANAGEMENT OF CERVICAL
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
EPITHELIAL OVARIAN CANCER IN OLDER
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
TAN AND KAYE Chemotherapy for Patie
Page 461 and 462:
TAN AND KAYE TABLE 1. Overall Respo
Page 463 and 464:
TAN AND KAYE The role of fırst-lin
Page 465 and 466:
TAN AND KAYE Disclosures of Potenti
Page 467 and 468:
HEAD AND NECK CANCER Best of the Re
Page 469 and 470:
ECONOMOPOULOU, BOURHIS, AND PSYRRI
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
TARGETING THE PI3K PATHWAY IN HNSCC
Page 477 and 478:
Page 479 and 480:
Page 481 and 482:
HEALTH SERVICES RESEARCH AND QUALIT
Page 483 and 484:
COMPARATIVE EFFECTIVENESS RESEARCH
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
MOY ET AL The Impact of Industry on
Page 491 and 492:
MOY ET AL tended. However, there ar
Page 493 and 494:
MOY ET AL Unfortunately, disclosure
Page 495 and 496:
MOY ET AL References 1. Bekelman JE
Page 497 and 498:
HEALTH SERVICES RESEARCH AND QUALIT
Page 499 and 500:
LAWRENCE N. SHULMAN will never be e
Page 501 and 502:
LAWRENCE N. SHULMAN data can be ver
Page 503 and 504:
LEUKEMIA, MYELODYSPLASIA, AND TRANS
Page 505 and 506:
DAVID I. MARKS TABLE 1. Prospective
Page 507 and 508:
DAVID I. MARKS FIGURE 2. Survival o
Page 509 and 510:
DAVID I. MARKS who received RIC all
Page 511 and 512:
DAVID I. MARKS Chimeric antigen rec
Page 513 and 514:
ADELE K. FIELDING Treatment of Phil
Page 515 and 516:
ADELE K. FIELDING confounded by the
Page 517 and 518:
ADELE K. FIELDING which include mor
Page 519 and 520:
ADELE K. FIELDING 12. Bassan R, Ros
Page 521 and 522:
SADELAIN ET AL CD19 CAR Therapy for
Page 523 and 524:
SADELAIN ET AL CAR T cell infusion,
Page 525 and 526:
LEUKEMIA, MYELODYSPLASIA, AND TRANS
Page 527 and 528:
KREM AND GOPAL TABLE 1. Median Ages
Page 529 and 530:
KREM AND GOPAL TABLE 3. Selected Ra
Page 531 and 532:
KREM AND GOPAL activated protein ki
Page 533 and 534:
KREM AND GOPAL References 1. Coiff
Page 535 and 536:
KREM AND GOPAL (NCT00796731). Paper
Page 537 and 538:
H. JOACHIM DEEG tumor, hypertension
Page 539 and 540:
H. JOACHIM DEEG fıcation for the d
Page 541 and 542:
H. JOACHIM DEEG tation for recurren
Page 543 and 544:
RECOGNIZING AND MANAGING HIGH-RISK
Page 545 and 546:
Page 547 and 548:
Page 549 and 550:
Page 551 and 552:
RISK STRATIFICATION IN PATIENTS WIT
Page 553 and 554:
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
JEAN-JACQUES KILADJIAN Scores predi
Page 561 and 562:
JEAN-JACQUES KILADJIAN in reducing
Page 563 and 564:
JEAN-JACQUES KILADJIAN ideal candid
Page 565 and 566:
JEAN-JACQUES KILADJIAN thrombocythe
Page 567 and 568:
ODENIKE, ONIDA, AND PADRON Myelodys
Page 569 and 570:
ODENIKE, ONIDA, AND PADRON TABLE 1.
Page 571 and 572:
ODENIKE, ONIDA, AND PADRON HMA trea
Page 573 and 574:
ODENIKE, ONIDA, AND PADRON as phase
Page 575 and 576:
ODENIKE, ONIDA, AND PADRON predicts
Page 577 and 578:
ODENIKE, ONIDA, AND PADRON mendatio
Page 579 and 580:
ODENIKE, ONIDA, AND PADRON plantati
Page 581 and 582:
ODENIKE, ONIDA, AND PADRON a progno
Page 583 and 584:
MARTINS, REYNOLDS, AND RIELY Beyond
Page 585 and 586:
MARTINS, REYNOLDS, AND RIELY vival
Page 587 and 588:
MARTINS, REYNOLDS, AND RIELY 4. Pai
Page 589 and 590:
SQUAMOUS, SMALL CELL, AND RARE LUNG
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
LUNG CANCER Positive Trials in Lung
Page 607 and 608:
EXPECTATIONS IN THE CARE OF LUNG CA
Page 609 and 610:
EXPECTATIONS IN THE CARE OF LUNG CA
Page 611 and 612:
LUNG CANCER Promises and Pitfalls o
Page 613 and 614:
VALUE OF LUNG CANCER CT SCREENING n
Page 615 and 616:
VALUE OF LUNG CANCER CT SCREENING T
Page 617 and 618:
VALUE OF LUNG CANCER CT SCREENING L
Page 619 and 620:
VALUE OF LUNG CANCER CT SCREENING r
Page 621 and 622:
SURGICAL MANAGEMENT OF STAGE IIIA N
Page 623 and 624:
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
CURRENT STANDARDS AND CLINICAL TRIA
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
MANAGEMENT OF DLBCL BASED ON MOLECU
Page 637 and 638:
Page 639 and 640:
Page 641 and 642:
Page 643 and 644:
Page 645 and 646:
COO IN DLBCL: ARE THE ASSAYS READY
Page 647 and 648:
Page 649 and 650:
Page 651 and 652:
Page 653 and 654:
LYMPHOMA AND PLASMA CELL DISORDERS
Page 655 and 656:
NOVEL TREATMENTS FOR T-CELL LYMPHOM
Page 657 and 658:
Page 659 and 660:
Page 661 and 662:
Page 663 and 664:
Page 665 and 666:
NEW DRUGS IN HODGKIN LYMPHOMA Novel
Page 667 and 668:
NEW DRUGS IN HODGKIN LYMPHOMA level
Page 669 and 670:
LYMPHOMA AND PLASMA CELL DISORDERS
Page 671 and 672:
SMOLDERING MULTIPLE MYELOMA TABLE 1
Page 673 and 674:
SMOLDERING MULTIPLE MYELOMA SIDEBAR
Page 675 and 676:
SMOLDERING MULTIPLE MYELOMA was rep
Page 677 and 678:
SMOLDERING MULTIPLE MYELOMA Disclos
Page 679 and 680:
BIOMARKER-DRIVEN THERAPY IN MYELOMA
Page 681 and 682:
Page 683 and 684:
Page 685 and 686:
Page 687 and 688:
Page 689 and 690:
Page 691 and 692:
SEQUENCING MYELOMA TREATMENTS imens
Page 693 and 694:
SEQUENCING MYELOMA TREATMENTS TABLE
Page 695 and 696:
SEQUENCING MYELOMA TREATMENTS with
Page 697 and 698:
SEQUENCING MYELOMA TREATMENTS 45. K
Page 699 and 700:
STILGENBAUER, FURMAN, AND ZENT Mana
Page 701 and 702:
STILGENBAUER, FURMAN, AND ZENT FIGU
Page 703 and 704:
STILGENBAUER, FURMAN, AND ZENT pare
Page 705 and 706:
STILGENBAUER, FURMAN, AND ZENT 40%
Page 707 and 708:
STILGENBAUER, FURMAN, AND ZENT prog
Page 709 and 710:
STILGENBAUER, FURMAN, AND ZENT stud
Page 711 and 712:
MELANOMA/SKIN CANCERS Cutaneous Squ
Page 713 and 714:
SANDRO V. PORCEDDU A review by Alam
Page 715 and 716:
SANDRO V. PORCEDDU ADJUVANT RADIATI
Page 717 and 718:
SANDRO V. PORCEDDU 15. Andruchow JL
Page 719 and 720:
TOTHILL, ESTALL, AND RISCHIN replic
Page 721 and 722:
TOTHILL, ESTALL, AND RISCHIN ported
Page 723 and 724:
TOTHILL, ESTALL, AND RISCHIN Disclo
Page 725 and 726:
TOTHILL, ESTALL, AND RISCHIN sis an
Page 727 and 728:
GRÜNHAGEN, KROON, AND VERHOEF Perf
Page 729 and 730:
GRÜNHAGEN, KROON, AND VERHOEF that
Page 731 and 732:
GRÜNHAGEN, KROON, AND VERHOEF syst
Page 733 and 734:
GRÜNHAGEN, KROON, AND VERHOEF 26.
Page 735 and 736:
AHMAD A. TARHINI patients; neoadjuv
Page 737 and 738:
AHMAD A. TARHINI addition, HDI regu
Page 739 and 740:
AHMAD A. TARHINI with earlier disea
Page 741 and 742:
AHMAD A. TARHINI immune cells withi
Page 743 and 744:
TARGETED THERAPY IN MELANOMA Achiev
Page 745 and 746:
TARGETED THERAPY IN MELANOMA BRAF V
Page 747 and 748:
TARGETED THERAPY IN MELANOMA AKT/mT
Page 749 and 750:
TARGETED THERAPY IN MELANOMA variet
Page 751 and 752:
TARGETED THERAPY IN MELANOMA come b
Page 753 and 754:
PATIENT AND SURVIVOR CARE Challenge
Page 755 and 756:
TREATING OLDER ADULTS WITH CANCER T
Page 757 and 758:
TREATING OLDER ADULTS WITH CANCER A
Page 759 and 760:
TREATING OLDER ADULTS WITH CANCER m
Page 761 and 762:
TREATING OLDER ADULTS WITH CANCER e
Page 763 and 764:
PATIENT AND SURVIVOR CARE Depressio
Page 765 and 766:
CAVALETTI, ALBERTI, AND MARMIROLI K
Page 767 and 768:
CAVALETTI, ALBERTI, AND MARMIROLI o
Page 769 and 770:
CAVALETTI, ALBERTI, AND MARMIROLI p
Page 771 and 772:
CAVALETTI, ALBERTI, AND MARMIROLI w
Page 773 and 774:
STANDARDIZING CARE FOR ADULT CANCER
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
PATIENT AND SURVIVOR CARE Managing
Page 781 and 782:
SEXUAL HEALING IN MEN ON HORMONE TH
Page 783 and 784:
SEXUAL HEALING IN MEN ON HORMONE TH
Page 785 and 786:
BONE HEALTH AND ENDOCRINE THERAPY I
Page 787 and 788:
Page 789 and 790:
Page 791 and 792:
Page 793 and 794:
ENDOCRINE THERAPY AND ITS EFFECT ON
Page 795 and 796:
Page 797 and 798:
Page 799 and 800:
Page 801 and 802:
ASSURING QUALITY CANCER SURVIVORSHI
Page 803 and 804:
Page 805 and 806:
Page 807 and 808:
Page 809 and 810:
Page 811 and 812:
CANCER PAIN MANAGEMENT Cancer Pain
Page 813 and 814:
CANCER PAIN MANAGEMENT Table 2. Ext
Page 815 and 816:
CANCER PAIN MANAGEMENT Table 4. Fac
Page 817 and 818:
CANCER PAIN MANAGEMENT Disclosures
Page 819 and 820:
MOLECULAR GENETIC PROFILING IN PEDI
Page 821 and 822:
Page 823 and 824:
Page 825 and 826:
Page 827 and 828:
ARMENIAN, KREMER, AND SKLAR Approac
Page 829 and 830:
ARMENIAN, KREMER, AND SKLAR TABLE 1
Page 831 and 832:
ARMENIAN, KREMER, AND SKLAR Additio
Page 833 and 834:
ARMENIAN, KREMER, AND SKLAR vivors.
Page 835 and 836:
ARMENIAN, KREMER, AND SKLAR 59. Oef
Page 837 and 838:
RIOTH, OSTERMAN, AND WARNER Advance
Page 839 and 840:
RIOTH, OSTERMAN, AND WARNER FIGURE
Page 841 and 842:
RIOTH, OSTERMAN, AND WARNER TABLE 1
Page 843 and 844:
RIOTH, OSTERMAN, AND WARNER mens wi
Page 845 and 846:
MICHAEL A. THOMPSON Using Social Me
Page 847 and 848:
MICHAEL A. THOMPSON about public he
Page 849 and 850:
MICHAEL A. THOMPSON Disclosures of
Page 851 and 852:
LAURA E. STRONG The Past, Present,
Page 853 and 854:
LAURA E. STRONG HOW ARE PROS USED I
Page 855 and 856:
LAURA E. STRONG patients vs clinici
Page 857 and 858:
KOSTY, ACHESON, AND TETZLAFF Clinic
Page 859 and 860:
KOSTY, ACHESON, AND TETZLAFF ical p
Page 861 and 862:
KOSTY, ACHESON, AND TETZLAFF groups
Page 863 and 864:
SARCOMA Adjuvant Treatment of Soft
Page 865 and 866:
PAOLO G. CASALI institution to anot
Page 867 and 868:
PAOLO G. CASALI ever, this trial sh
Page 869 and 870:
DICKIE, HAAS, AND O’SULLIVAN Adju
Page 871 and 872:
DICKIE, HAAS, AND O’SULLIVAN use
Page 873 and 874:
DICKIE, HAAS, AND O’SULLIVAN FIGU
Page 875 and 876:
DICKIE, HAAS, AND O’SULLIVAN dose
Page 877 and 878:
DICKIE, HAAS, AND O’SULLIVAN ther
Page 879 and 880:
PAUL A. MEYERS Systemic Therapy for
Page 881 and 882:
PAUL A. MEYERS TABLE 2. Chemotherap
Page 883 and 884:
TINOCO ET AL The Biology and Manage
Page 885 and 886:
TINOCO ET AL TABLE 2. Malignant Car
Page 887 and 888:
TINOCO ET AL FIGURE 1. The Metaboli
Page 889 and 890:
TINOCO ET AL mesenchymal, clear cel
Page 891 and 892:
BENJAMIN ET AL Chemotherapy for Bon
Page 893 and 894:
BENJAMIN ET AL FIGURE 1. Continuous
Page 895 and 896:
BENJAMIN ET AL Disclosures of Poten
Page 897 and 898:
INDIVIDUALIZED THERAPY FOR LIPOSARC
Page 899 and 900:
Page 901 and 902:
Page 903 and 904:
TUMOR BIOLOGY Implications of Intra
Page 905 and 906:
CLONAL EVOLUTION OF TUMOR HETEROGEN
Page 907 and 908:
CLONAL EVOLUTION OF TUMOR HETEROGEN
Page 909 and 910:
PET DOGS POISED TO ADVANCE CANCER P
Page 911 and 912:
Page 913 and 914:
Page 915 and 916:
TUMOR BIOLOGY Targeting Cancer Meta
Page 917 and 918:
TARGETING THE DEREGULATED METABOLIS
Page 919 and 920:
Page 921 and 922:
Page 924:
This publication is supported by an
show all

NcXHF

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?